Two identified orexin receptors (OX1 and OX2 ... For example, a recent systematic review and meta-analysis revealed that the prevalence of any substance use disorder in treatment-seeking patients ...

Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia QUVIVIQ™ (daridorexant) 25 and 50 mg was recently approved and is expected ...

Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes that Centessa Pharmaceuticals has initiated a Phase 2 trial of ORX750, an investigational, orally ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

Daridorexant is a dual orexin receptor antagonist being developed ... Recent data from Korea’s Health Insurance Review and Assessment Service (HIRA) revealed that the number of chronic insomnia ...

revealing a mutation in the hypocretin/orexin-2 receptor gene as the cause of canine narcolepsy. According to Yanagisawa, the journal’s editor invited him to peer-review the paper, tipping him ...